Schering-Plough’s initiation of human trials prompted a $1 million payment to Pharmacopeia. The compound, PS948115, identified through the firms’ partnership, is being evaluated as a treatment for respiratory disease.
“The Schering-Plough collaboration continues to yield very attractive therapeutic candidates,” points out Les Browne, Ph.D., president and CEO of Pharmacopeia. In March the companies reported Phase I evaluation of an anti-inflammatory compound and in April they selected another candidate for preclinical evaluation.
Schering-Plough is solely responsible for further development and commercialization. Pharmacopeia is eligible to receive additional milestone payments depending on development success and royalties on resulting products.